drugset / Trial / NCT05933200

A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

NCT05933200

Phase 3 Active not recruiting 69 enrolled Ultragenyx Pharmaceutical Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).

Timeline

Start
2023-02-28
Primary completion
2027-08
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Triheptanoin Other / unclassified Oral